Gotham Asset Management LLC Acquires 6,434 Shares of Qiagen (NYSE:QGEN)

Gotham Asset Management LLC increased its holdings in Qiagen (NYSE:QGEN - Free Report) by 6.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 113,414 shares of the company's stock after purchasing an additional 6,434 shares during the period. Gotham Asset Management LLC owned approximately 0.05% of Qiagen worth $5,050,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Groupama Asset Managment increased its holdings in shares of Qiagen by 8,074.0% in the fourth quarter. Groupama Asset Managment now owns 31,817,740 shares of the company's stock valued at $1,416,844,000 after purchasing an additional 32,216,761 shares in the last quarter. Norges Bank acquired a new stake in shares of Qiagen in the fourth quarter valued at approximately $181,529,000. Massachusetts Financial Services Co. MA increased its holdings in shares of Qiagen by 9.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 25,319,332 shares of the company's stock valued at $1,127,470,000 after purchasing an additional 2,202,040 shares in the last quarter. Caisse Des Depots ET Consignations acquired a new stake in shares of Qiagen in the fourth quarter valued at approximately $53,991,000. Finally, Barclays PLC increased its holdings in shares of Qiagen by 170.6% in the third quarter. Barclays PLC now owns 1,849,004 shares of the company's stock valued at $84,259,000 after purchasing an additional 1,165,594 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on QGEN. Baird R W lowered shares of Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. UBS Group lowered their price target on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating for the company in a report on Friday, February 7th. Robert W. Baird raised their price objective on shares of Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Redburn Atlantic cut shares of Qiagen from a "buy" rating to a "neutral" rating in a research note on Friday, April 4th. Finally, StockNews.com raised shares of Qiagen from a "buy" rating to a "strong-buy" rating in a research note on Thursday. Seven equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $48.42.

Qiagen Trading Up 1.0%

Shares of NYSE QGEN traded up $0.41 during midday trading on Friday, reaching $42.65. 740,713 shares of the stock were exchanged, compared to its average volume of 1,145,523. The business has a 50-day simple moving average of $40.97 and a two-hundred day simple moving average of $41.80. The company has a market capitalization of $9.48 billion, a price-to-earnings ratio of 118.76, a P/E/G ratio of 2.39 and a beta of 0.67. Qiagen has a 12 month low of $37.63 and a 12 month high of $49.30. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.61 and a quick ratio of 3.09.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, topping analysts' consensus estimates of $0.50 by $0.05. The company had revenue of $483.46 million for the quarter, compared to analysts' expectations of $465.66 million. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The business's quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the firm posted $0.44 earnings per share. As a group, equities research analysts expect that Qiagen will post 2.26 EPS for the current year.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.